CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
CRISPR-mediated gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease resulted in functional human leukocytes in mice after transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have shown that disease-causing genetic errors can be corrected using CRISPR/Cas9 in long-term engrafting HSPCs that are preserved in downstream effector lineages15,16,24,25.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [24]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · cited 1×
“CRISPR/Cas9, guided by a single-guide RNA, achieves efficient doublestranded DNA breaks (9, 10).”
BackgroundMultiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationThe new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624
Cas9 as a versatile tool for engineering biology
Mali, P., Esvelt, K. M., & Church, G. M. (2013) · Nature Methods · doi:10.1038/nmeth.2649 · Cited by 1,197 · cited 1×
“CRISPR/Cas9, guided by a single-guide RNA, achieves efficient doublestranded DNA breaks (9, 10).”
BackgroundLentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025
Genome editing in rice and wheat using the CRISPR/Cas system
Shan, Q., Wang, Y., Li, J., & Gao, C. (2014) · Nature Protocols · doi:10.1038/nprot.2014.157 · Cited by 763
Research works printed but not linked: 1
- J. A. Doudna E. J. Sontheimer Eds. The Use of CRISPR/Cas9 ZFNs and TALENs in Generating Site-Specific Genome Alterations vol. 546 of Methods in Enzymology (Academic Press 2014) pp. xix–xx.
Cited by
Items 101–200 of 264
Advantages and Limitations of Gene Therapy and Gene Editing for Friedreich’s Ataxia
Sivakumar, A., & Cherqui, S. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.903139 · Cited by 40
Controlling genetic heterogeneity in gene-edited hematopoietic stem cells by single-cell expansion
Becker, H. J., Ishida, R., Wilkinson, A. C., Kimura, T., Lee, M. S. J., Coban, C., Ota, Y., Tanaka, Y., Roskamp, M., Sano, T., et al. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.06.002 · Cited by 32
Keller, M. D., Notarangelo, L. D., & Malech, H. L. (2018) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piy011 · Cited by 32
Self-citationRecent advances in primary immunodeficiency: from molecular diagnosis to treatment
Bucciol, G., & Meyts, I. (2020) · F1000Research · doi:10.12688/f1000research.21553.1 · Cited by 34
Gene Editing for the Treatment of Primary Immunodeficiency Diseases
Rai, R., Thrasher, A. J., & Cavazza, A. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.185 · Cited by 31
“Upon transplantation of manipulated HSPCs into immunodeficient mice, 15–20% of corrected cells persisted in transplanted animals for up to 5 months, with restored physiological expression of the gp91 in mature phagocytes and proper functionality of the NADPH oxidase.(24) Despite these encouraging data, whether such ge…”
BackgroundSharma, R., Dever, D. P., Lee, C. M., Azizi, A., Pan, Y., Camarena, J., Köhnke, T., Bao, G., Porteus, M. H., & Majeti, R. (2021) · Nature Communications · doi:10.1038/s41467-020-20792-y · Cited by 32
Dudek, A. M., & Porteus, M. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660302 · Cited by 32
“By definition, true long-term hematopoietic stem cells (LT-HSCs) have self-renewal capacity and have multi-lineage potential to reconstitute every cell-type of the hematopoietic system, including immune system cells (25).”
BackgroundCRISPRedict: a CRISPR-Cas9 web tool for interpretable efficiency predictions
Konstantakos, V., Nentidis, A., Krithara, A., & Παλιούρας, Γ. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac466 · Cited by 33
“(22) used CRISPR-Cas9 to repair a mutation in the CYBB gene of CD34+ hematopoietic stem and progenitor cells (HSPCs) from patients with the immunodeficiency disorder X-CGD.”
MethodLee, B., Gin, A. L., Wu, C., Singh, K., Grice, M. Z., Mortlock, R. D., Abraham, D. M., Fan, X., Zhou, Y., Aljanahi, A. A., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.02.010 · Cited by 33
Self-citationFunctional neutrophil disorders: Chronic granulomatous disease and beyond
Zerbe, C. S., & Holland, S. M. (2024) · Immunological Reviews · doi:10.1111/imr.13308 · Cited by 31
“89,90”
CRISPR-based therapeutic genome editing for inherited blood disorders
Levesque, S., & Bauer, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01236-y · Cited by 39
“HDR and ABE strategies have been developed to correct the prototypical X-linked chronic granulomatous disease (X-GCD) mutation in the CYBB gene (the R226X mutant of the p91 phox subunit) 104,156 .”
Ameratunga, R., Lehnert, K., & Woon, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02678 · Cited by 30
Historical Perspective on the Current Renaissance for Hematopoietic Stem Cell Gene Therapy
Kohn, D. B. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.006 · Cited by 30
Uchida, N., Li, L., Nassehi, T., Drysdale, C. M., Yapundich, M., Gamer, J., Haro‐Mora, J. J., Demirci, S., Leonard, A. K., Bonifacino, A. C., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100247 · Cited by 35
“Similar editing ratios among subpopulations were previously described in healthy donor CD34 cells with another target.(33) These data demonstrate that gene editing efficiency does not vary between the subpopulations of CD34 cells that we evaluated under the present conditions.”
ResultSelf-citationBzhilyanskaya, V., Ma, L., Liu, S., Fox, L. R., Whittaker, M. N., Meis, R. J., Choi, U., Lawson, A., Ma, M., Theobald, N., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj6779 · Cited by 28
“At 2 days after EP, CD34 + HSPCs treated with positive control CRISPR-Cas9 nuclease and gRNA ( 17 ) or puromycin, a known cytotoxic agent, resulted in abundant comets (Fig.”
BackgroundMethodInfluentialSelf-citationGene therapy for primary immunodeficiencies
Fox, T. A., & Booth, C. (2020) · British Journal of Haematology · doi:10.1111/bjh.17269 · Cited by 29
“Studies have been published which demonstrate promising gene editing approaches for SCID-X1, WAS, X-CGD, hyper IgM syndrome, IPEX syndrome and X-linked agammaglobulinaemia (34, 40, 50, 122-124).”
BackgroundInfluentialBustamante, O. Q., Fañanas-Baquero, S., Orman, I., Torres-Ruiz, R., Duchateau, P. N., Poirot, L., Gouble, A., Bueren, J. A., & Segovia, J. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223775 · Cited by 26
“Different groups have reported efficient gene editing to correct genetic blood cell diseases such as X-linked severe combined immunodeficiency (SCID-X1)[18], JAK3 severe combined immunodeficiency[19], X-CGD [20], β-thalassemia[21–24], sickle cell anemia[21, 23–28] and Fanconi Anemia[29].”
BackgroundSalekdeh, P. R., Ma’mani, L., Tavakkoly‐Bazzaz, J., Mousavi, H., Modarressi, M. H., & Salekdeh, G. H. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00838-z · Cited by 28
Lu, Y., Zhou, Y., Ju, R., & Chen, J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.10.13 · Cited by 27
“This would be beneficial for patients suffering from malignancy hematologic disease (45-47), and for those with end-stage organ failure caused by genetic disorders, such as polycystic renal disease and hepatolenticular degeneration, to receive autologous organs for transplantation.”
BackgroundCastiello, M. C., Brandas, C., Ferrari, S., Porcellini, S., Sacchetti, N., Canarutto, D., Draghici, E., Merelli, I., Barcella, M., Pelosi, G., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adh8162 · Cited by 25
Self-citationVery Early-Onset Inflammatory Manifestations of X-Linked Chronic Granulomatous Disease
Labrosse, R., Abou-Diab, J., Blincoe, A., Cros, G., Luu, T. M., Deslandres, C., Dirks, M., Fazilleau, L., Ovetchkine, P., Teira, P., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01167 · Cited by 25
Conti, A., Giannetti, K., Midena, F., Beretta, S., Gualandi, N., Marco, R. D., Carsana, E., Varesi, A., Tavella, T., Alessandrini, L., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102157 · Cited by 38
The Impact of CRISPR-Cas9 on Age-related Disorders: From Pathology to Therapy
Caobi, A., Dutta, R. K., Garbinski, L. D., Esteban-López, M., Ceyhan, Y., Andre, M., Manevski, M., Ojha, C. R., Lapierre, J., Tiwari, S., et al. (2020) · Aging and Disease · doi:10.14336/ad.2019.0927 · Cited by 28
“mice and human cells successfully eradicating genetic diseases in not only mice, but also its progeny [42, 43].”
BackgroundMaganti, H. B., Bailey, A. J.-M., Kirkham, A. M., Shorr, R., Pineault, N., & Allan, D. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0520 · Cited by 28
Advances in gene therapy for inborn errors of immunity
de Bruin, L. M. O., Lankester, A. C., & Staal, F. J. T. (2023) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000952 · Cited by 25
Genome and Epigenome Editing to Treat Disorders of the Hematopoietic System
Mussolino, C., Alzubi, J., Pennucci, V., Turchiano, G., & Cathomen, T. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.149 · Cited by 24
“19 In conclusion, gene targeting in human HSCs to treat PIDs has become a reality in a preclinical context.”
Shen, X., Beasley, S., Putman, J. N., Li, Y., Prakash, T. P., Rigo, F., Напиерала, М., & Corey, D. R. (2019) · RNA · doi:10.1261/rna.071290.119 · Cited by 23
“While theMaxCyte system is commonly used for engineering of multiple primary cell types by transfecting plasmid DNA, mRNA, and RNPs (De Ravin et al. 2016, 2017; Hung et al. 2018), there were no published reports www.rnajournal.org 1119 using ASOs or dsRNAs and our first goal was to identify…”
BackgroundGene and RNA Editing: Revolutionary Approaches to Treating Diseases
Li, J., Huang, J., Liao, Y., Hu, T., Wang, C., Zhang, W., & Huang, C. (2025) · MedComm · doi:10.1002/mco2.70389 · Cited by 31
Fañanas-Baquero, S., Bustamante, O. Q., Dever, D. P., Alberquilla, O., Sánchez‐Domínguez, R., Camarena, J., Ojeda-Pérez, I., Dessy-Rodríguez, M., Turk, R., Schubert, M. S., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.001 · Cited by 23
Cruz, L. J., Rezaei, S., Grosveld, F. G., Philipsen, S., & Eich, C. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.1030285 · Cited by 26
Yazdi, Z. F., Roshannezhad, S., Sharif, S., & Abbaszadegan, M. R. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05908-y · Cited by 25
Applications of Gene Editing and Nanotechnology in Stem Cell-Based Therapies for Human Diseases
Bolideei, M., Barzigar, R., Gahrouei, R. B., Mohebbi, E., Haider, K. H., Paul, S., Paul, M. K., & Mehran, M. J. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10857-0 · Cited by 28
CRISPR‐Cas9: A cornerstone for the evolution of precision medicine
Razzouk, S. (2018) · Annals of Human Genetics · doi:10.1111/ahg.12271 · Cited by 25
“After double-positive transfection and magnetic sorting of the final isolated clones, efficiency became is 83% Omer et al., 2017 • Differentiation of corrected iPSC into hepatocytes with LDLR expression and normalization of receptor-mediated LDL internalization • No off-target mutations Fanconi anemia (FA) Fanconi ane…”
BackgroundInfluentialAdvances in CRISPR/Cas gene therapy for inborn errors of immunity
Liu, X., Li, G., Liu, Y., Zhou, F., Huang, X., & Li, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111777 · Cited by 28
“Transplanting gene-repaired X-CGD HSPCs into NSG mice resulted in efficient engraftment and production of functional mature human myeloid and lymphoid cells for up to five months (227).”
BackgroundMethodInfluentialOldani, G., Peloso, A., Lacotte, S., Meier, R. P. H., & Toso, C. (2017) · Xenotransplantation · doi:10.1111/xen.12327 · Cited by 23
Genome-edited adult stem cells: Next-generation advanced therapy medicinal products
Benabdellah, K., Sánchez-Hernández, S., Aguilar-González, A., Maldonado‐Pérez, N., Gutiérrez-Guerrero, A., Cortijo-Gutierréz, M., Ramos-Hernández, I., Tristán‐Manzano, M., Galindo‐Moreno, P., Herrera, C., et al. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0338 · Cited by 23
“By disrupting Bcl11a gene expression in erythroid cells, the fetal γ-globin will be expressed in adults forming fetal hemoglobin (αγ) which should restore normal function have shown that AAV6 harboring the donor DNA could also be combined with TALEN mRNA or CRISPR/Cas9 RNP to restore X-linked hyper-IgM syndrome.68 Usi…”
BackgroundMethodInfluentialFunction and Safety of Lentivirus-Mediated Gene Transfer for CSF2RA -Deficiency
Hetzel, M., Suzuki, T., Hashtchin, A. R., Arumugam, P. I., Carey, B. C., Schwabbauer, M., Kuhn, A., Meyer, J., Schambach, A., van der Loo, J. C. M., et al. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.092 · Cited by 22
CRISPR delivery systems for organ-specific targeting: Advances and challenges
Du, J., Wu, Q., Liu, C., Wang, N., & Gong, C. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100048 · Cited by 21
Dudek, A. M., Feist, W. N., Sasu, E. J., Luna, S. E., Ben-Efraim, K., Bak, R. O., Cepika, A.-M., & Porteus, M. H. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.03.002 · Cited by 19
Gene Editing for Inherited Red Blood Cell Diseases
Bustamante, O. Q., Fañanas-Baquero, S., Dessy-Rodríguez, M., Ojeda-Pérez, I., & Segovia, J. C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.848261 · Cited by 20
Rai, R., Naseem, A., Vetharoy, W., Steinberg, Z., Thrasher, A. J., Santilli, G., & Cavazza, A. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.02.014 · Cited by 21
Allen, D. G., Kalter, N., Rosenberg, M., & Hendel, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051329 · Cited by 20
“ssODNs have been used to correct the HBB and CYBB genes, respectively, both in vitro (in isolated HSPCs) and in vivo (in mice) [22,26,34].”
BackgroundMethodPoletto, É., Colella, P., Vera, L. N. P., Khan, S. A., Tomatsu, S., Baldo, G., & Gomez‐Ospina, N. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.009 · Cited by 20
Molaei, Z., Jabbarpour, Z., Omidkhoda, A., & Ahmadbeigi, N. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03848-4 · Cited by 23
Recent advances in understanding and treating chronic granulomatous disease
Gennery, A. R. (2017) · F1000Research · doi:10.12688/f1000research.11789.1 · Cited by 18
Wrona, D., Pastukhov, O., Pritchard, R. S., Raimondi, F., Tchinda, J., Jínek, M., Siler, U., & Reichenbach, J. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.015 · Cited by 19
Correcting inborn errors of immunity: From viral mediated gene addition to gene editing
Castiello, M. C., Ferrari, S., & VILLA, A. M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101731 · Cited by 17
CRISPR/Cas9 genome engineering in hematopoietic cells
Sürün, D., von Melchner, H., & Schnütgen, F. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.08.001 · Cited by 16
An in vitro site-specific cleavage assay of CRISPR-Cas9 using a personal glucose meter
Gong, S., Chen, Y., Pan, W., Li, N., & Tang, B. (2020) · Chemical Communications · doi:10.1039/d0cc03505j · Cited by 16
Gene surgery: Potential applications for human diseases
El-Kenawy, A. E.-M., Benarba, B., Neves, A. F., Araújo, T. G., Tan, B. L., & Gouri, A. (2019) · EXCLI journal · doi:10.17179/excli2019-1833 · Cited by 19
“Additionally, De Ravin et al. (2017) also demonstrated that CRISPR/Cas9 could repair a mutation in the CYBB gene of CD34+ hematopoietic stem and progenitor cells (HSPCs) for those of the patients with immunodeficiency disorder Xlinked chronic granulomatous disease (XCGD).”
BackgroundEmerging trends in gene and cell therapy: CRISPR in DNA editing and beyond
Ji, R., Chen, Q., & Zhang, Y. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102459 · Cited by 19
A Curative DNA Code for Hematopoietic Defects
Porteus, M. H., Pavel-Dinu, M., & Pai, S. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.05.002 · Cited by 18
Advances and Obstacles in Homology-Mediated Gene Editing of Hematopoietic Stem Cells
Salisbury-Ruf, C. T., & Larochelle, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030513 · Cited by 15
“mPB, X-CGD subjects Cas9 mRNA + ssODN 31% AAVS1, gp91 ph◦x expression in HSPC-derived myeloid cells [71]”
BackgroundBAR-Seq clonal tracking of gene-edited cells
Ferrari, S., Beretta, S., Jacob, A., Cittaro, D., Albano, L., Merelli, I., Naldini, L., & Genovese, P. (2021) · Nature Protocols · doi:10.1038/s41596-021-00529-x · Cited by 15
Innovative Cell-Based Therapies and Conditioning to Cure RAG Deficiency
VILLA, A. M., Capo, V., & Castiello, M. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.607926 · Cited by 14
The New Frontiers of Gene Therapy and Gene Editing in Inflammatory Diseases
Romano, A. P. M., & Mortellaro, A. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.210 · Cited by 13
“17 Using a similar strategy, Merling et al. engineered ZFNs to target the shared region at the beginning of exon 2 in the NCF1 locus, which is the primary cause of p47-CGD.”
Sweeney, C. L., Choi, U., Liu, C., Koontz, S. M., Ha, S.-K., & Malech, H. L. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.005 · Cited by 14
Self-citationCRISPR/Cas systems usher in a new era of disease treatment and diagnosis
Li, R., Wang, Q., She, K., Lu, F., & Yang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00095-y · Cited by 14
Leiding, J. W., & Holland, S. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816768-7.00037-5 · Cited by 20
Neutrophils, an emerging new therapeutic platform
López-Arredondo, A., Cruz-Cárdenas, J. A., Cázares-Preciado, J. A., Timmins, N. E., & Brunck, M. E. G. (2024) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2024.103106 · Cited by 13
Pugliano, C. M., Berger, M. P., Ray, R. M., Sapkos, K., Wu, B., Laird, A., Ye, Y., Thomson, D., DeGottardi, M. Q., Khan, I., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101297 · Cited by 13
Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine
McCarthy, M. W. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1761333 · Cited by 13
“The CRISPR-Cas9 system can be used to manipulate and excise stretches of DNA that have profound relevance for human health, ranging from aggressive malignancies to mitochondrial storage diseases, as well as potential applications in the prevention and treatment of infectious diseases such as human immunodeficiency vir…”
BackgroundThe Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies
Shouval, D. S., Kowalik, M., & Snapper, S. B. (2018) · Journal of Clinical Immunology · doi:10.1007/s10875-018-0524-9 · Cited by 13
“In addition, novel CRISPR/Cas9-mediated gene editing approaches are in the pipeline [78].”
BackgroundWolff, J. H., & Mikkelsen, J. G. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1148650 · Cited by 15
Harnessing accurate mitochondrial DNA base editing mediated by DdCBEs in a predictable manner
Qiu, J., Wu, H., Xie, Q., Zhou, Y., Gao, Y., Liu, J., Jiang, X., Suo, L., & Kuang, Y. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1372211 · Cited by 12
Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy
Williams, D. A., Kohn, D. B., & Thrasher, A. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.058 · Cited by 11
CRISPR/Cas-Based Gene Editing Strategies for DOCK8 Immunodeficiency Syndrome
Ravendran, S., Hernández, S. S., König, S., & Bak, R. O. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.793010 · Cited by 12
Advances and highlights in primary immunodeficiencies in 2017
Chinen, J., & Cowan, M. J. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.016 · Cited by 11
Vojnits, K., Nakanishi, M., Porras, D. P., Kim, Y., Feng, Z., Golubeva, D., & Bhatia, M. (2022) · Molecules · doi:10.3390/molecules27082434 · Cited by 10
Gibbings, S. L., Haist, K. C., Nick, H. J., Frasch, S. C., Glass, T. H., Vestal, B. E., Danhorn, T., Mould, K. J., Henson, P. M., & Bratton, D. L. (2021) · Blood · doi:10.1182/blood.2021011798 · Cited by 11
Gene therapy for inborn error of immunity – current status and future perspectives
Mudde, A. C. A., & Booth, C. (2022) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000876 · Cited by 10
“Efforts should be made to make viral vector be improved in preclinical studies with successful scale up prior to the translation to clinical studies.”
Advances in gene therapy for hematologic disease and considerations for transfusion medicine
Reddy, O. L., Savani, B. N., Stroncek, D. F., & Panch, S. R. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.07.004 · Cited by 16
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight
Zhang, Z., Zhang, S., Wong, H. T., Li, D., & Feng, B. (2024) · BioDrugs · doi:10.1007/s40259-024-00654-5 · Cited by 11
“…and single-stranded oligonucleotides (ssODN; <200 nt) has previously led to the successful correction of HBB and CYBB mutations in human HSPCs [66, 67] and the efficient knock-in in mouse and rat embryos [68], which supported ssDNA donors as an attractive option because short homology arms at…”
Wolff, J. H., Skov, T. W., Haslund, D., Dorset, S. R., Revenfeld, A. L., Aussel, C., Jørgensen, S. E., Holm, M., Thomsen, M. K., Ammann, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62738-2 · Cited by 10
“…gene correction in CD34 + HSPCs by homology-directed repair (HDR) as a potential treatment for various blood disorders, including X-linked CGD 10,13 , X-linked hyper-IgM syndrome 14,15 , severe combined immuno-de fi ciency (SCID)-X1 16,17 , Wiskott – Aldrich Syndrome 18 , β - thalassemia 19,20 ,…”
Koyunlar, C., & de Pater, E. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.602182 · Cited by 10
CRISPR/Cas9 applications in gene therapy for primary immunodeficiency diseases
Ravin, S. S. D., & Brault, J. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20180157 · Cited by 10
Gene Editing in Chronic Granulomatous Disease
Sweeney, C. L., Merling, R. K., Ravin, S. S. D., Choi, U., & Malech, H. L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9424-3_36 · Cited by 9
Self-citationmRNA as a Tool for Gene Transfection in 3D Cell Culture for Future Regenerative Therapy
Uchida, S., Yanagihara, K., Matsui, A., Kataoka, K., & Itaka, K. (2020) · Micromachines · doi:10.3390/mi11040426 · Cited by 10
Efficient repair of human genetic defect by CRISPR/Cas9-mediated interlocus gene conversion
Yang, F., Wang, Y., Wang, Q., Pang, J., Liu, G., Yang, Y., Qin, S., Zhang, Y., Lai, Y., Fu, B., et al. (2023) · Life Medicine · doi:10.1093/lifemedi/lnad042 · Cited by 9
The Promises and Pitfalls of CRISPR-Mediated Base Editing in Stem Cells
Wong, P. K., Zamberi, N. N. M., Syafruddin, S. E., Cheah, F., Azmi, N., Law, J. X., & Chua, E. W. (2023) · The CRISPR Journal · doi:10.1089/crispr.2023.0013 · Cited by 9
Siow, K. M., Güngör, M., Wrona, D., Raimondi, F., Pastukhov, O., Tsapogas, P., Menzi, T., Schmitz, M., Kulcsár, P. I., Schwank, G., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102229 · Cited by 8
Castelli, A., Susani, L., Menale, C., Muggeo, S., Caldana, E., Strina, D., Cassani, B., Recordati, C., Scanziani, E., Ficara, F., et al. (2019) · Stem Cells · doi:10.1002/stem.3006 · Cited by 9
β-Hemoglobinopathies: The Test Bench for Genome Editing-Based Therapeutic Strategies
Barbarani, G., Łabędź, A., & Ronchi, A. E. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.571239 · Cited by 10
“…of the genome editing procedure: the development of new editing reagents [single-strand DNA donor templates (Park et al., 2019), modified sgRNA (De Ravin et al., 2017; Park et al., 2019), pre-complexed ribonucleoproteins (RNPs) (Gundry et al., 2016)] and their integration in improved platforms…”
MethodGutiérrez-Guerrero, A., Perian, S., Leray, A., Martinello, C., Abrey-Recalde, M. J., Costa, C., Herrero, C. I., Bouzelha, M., Álvarez‐Dorta, D., Gouin, S. G., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102495 · Cited by 7
CXCR4 Is a Potential Target for Anti-HIV Gene Therapy
Prokopovich, A. K., Litvinova, I. S., Zubkova, A. E., & Yudkin, D. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021187 · Cited by 7
White, N., Chalk, J. A., Hu, Y., Pins, S. M., Joseph, C. R., Antoniou, P., Wimberger, S., Svensson, S., Caetano-Silva, S. P., Mudde, A. C. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65182-4 · Cited by 10
“The results of the long-term (14 days) experiments can be influenced by the selective advantage/disadvantage produced by the specific genetic modification.”
Genome editing for blood disorders: state of the art and recent advances
Romito, M., Rai, R., Thrasher, A. J., & Cavazza, A. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20180147 · Cited by 7
Zhang, L., Li, K., Liu, Z., An, L., Wei, H., Pang, S., Cao, Z., Huang, X., Jin, X., & Ma, X. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.028 · Cited by 7
Engineering precision therapies: lessons and motivations from the clinic
Xie, M., Viviani, M., & Fussenegger, M. (2020) · Synthetic Biology · doi:10.1093/synbio/ysaa024 · Cited by 11
“Driven by the clinical success of Zynteglo and Strimvelis, many blood prosthesis therapies are currently under clinical trial, including treatments intended for sickle cell disease and b-thalassaemia (91–96), X-linked severe combined immunodeficiency (97), Wiskott-Aldrich syndrome (98) and chronic granuloma (99) (Supp…”
BackgroundLotfi, M., Ashouri, A., Mojarrad, M., Mozaffari‐Jovin, S., & Abbaszadegan, M. R. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00739-6 · Cited by 5
“For instance, CRISPR/Cas9 has been employed in sickle cell disease (SCD) [13, 14], cystic fibrosis [15, 16], Duchenne muscular dystrophy [17, 18], Huntington’s chorea disorder [19, 20], chronic granulomatous disease [21, 22] and hemophilia [23, 24].”
Whittaker, T. E., Moula, S. E., Bahal, S., Bakri, F. G., Hayajneh, W. A., Daoud, A. K., Naseem, A., Cavazza, A., Thrasher, A. J., & Santilli, G. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.114 · Cited by 5
“…of X-linked CGD (gp91 phox ) has been intensely investigated with both classical integrating lentiviral treatments 9 and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene editing techniques, 10,11 recently leading to successful lentiviral gene therapy clinical trials.”
Mudde, A. C. A., Kuo, C. Y., Kohn, D. B., & Booth, C. (2024) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2024.01.019 · Cited by 5
“…in gene repair rates was observed when comparing pretransplant data to posttransplant rates, but analysis of mouse peripheral blood showed stable gene repair levels over time as indicated by gp91-phox expression levels in human CD45 þ myeloid cells derived from gene-corrected CD34 þ HSCs. 78”
Sevim-Wunderlich, S., Dang, T., Rossius, J., Schnütgen, F., & Kühn, R. (2024) · Genes · doi:10.3390/genes15060706 · Cited by 5
Peng, F., Zhong, L.-L., Zhang, B., Zou, R., Nie, S., Tian, X., Deng, S., & He, X. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7318 · Cited by 5
“Gene therapy is still in the experimental stages, and it may take a number of years until it is commonly used as a treatment for CGD worldwide (27).”
BackgroundEngineered neutrophil, an emerging immune therapeutic strategy
Wang, J., Deng, T., Chen, R., Yang, L., Teng, Y., & Miao, J. (2025) · Innate Immunity · doi:10.1177/17534259251365803 · Cited by 4
Advances in site-specific gene editing for primary immune deficiencies
Kuo, C. Y. (2018) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000483 · Cited by 4
Gene Therapy for Primary Immunodeficiencies
Cicalese, M. P., & Aiuti, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-77674-3_21 · Cited by 4
Targeted genome editing for the correction or alleviation of primary Immunodeficiencies
Sipe, C. J., Vázquez, P. N. C., Skeate, J. G., McIvor, R. S., & Moriarity, B. S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.03.001 · Cited by 4
Long, J. D., Trope, E. C., Yang, J., Rector, K., & Kuo, C. Y. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.03.011 · Cited by 4
Gene therapy for primary immunodeficiencies: up-to-date
Chetty, K., & Booth, C. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1837108 · Cited by 4
“Direct reversion of a diseasecausing variant in a gene was trialed by correcting the most frequent mutation in CGD patients – the C676T substitution in exon 7 [88,89].”
Background
Metadata
- Authors
- De Ravin, S. S., Li, L., Wu, X., Choi, U., Allen, C., Koontz, S., Lee, J., Theobald-Whiting, N., Chu, J., Garofalo, M., Sweeney, C., Kardava, L., Moir, S., Viley, A., Natarajan, P., Su, L., Kuhns, D., Zarember, K. A., Peshwa, M. V., & Malech, H. L.
- Affiliations
- Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
- MaxCyte (United States) (US)
- Leidos Biomedical Research Inc. (United States) (US)
- National Institutes of Health (US)
- Corresponding author
- Li, Linhong
- Malech, Harry L.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-01-11
- Volume
- 9
- Issue
- 372
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2577713652
- Semantic Scholar
- 531bffc692cccebccbf571ed886fd2766c50f091
- Cited by
- 258
- References
- 32
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 23 · 2023: 19 · 2022: 23 · 2021: 36 · 2020: 39 · 2019: 35 · 2018: 26 · 2017: 25
- FWCI
- 13.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Intramural Research Program of NIAID
- NIH (Z01-A1-00644, Z01-A1-00988)
- Maryland Stem Cell Research Fund (#2015-MSCRFP-1752)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9 genome editing, X-linked chronic granulomatous disease, hematopoietic stem cells, CYBB gene, gene correction, engraftment
- MeSH terms
- NADPH Oxidase 2, Animals, Cell Differentiation, DNA Repair, Female, Granulomatous Disease, Chronic, Hematopoietic Stem Cells, Humans, Mutation, Oligonucleotides, Genetic Therapy, Mutagenesis, Mice, SCID, Mice, Inbred NOD, Antigens, CD34, Mice, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.